OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 19:09 UTC. Every row links to its source record.

H3C2 H3 clustered histone 2

ENSG00000286522 · protein coding · Open Targets profile

Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling.

In 14 of 15 cancers, the evidence for H3C2 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751gliomagliomaglioma: somatic 0.46glioma: germline 0.61breast carcinomabreast carcinomabreast carcinoma: somatic 0.46melanomamelanomamelanoma: somatic 0.46diffuse large B-cell lymphomadiffuse large B-cell lymphomadiffuse large B-cell lymphoma: somatic 0.53breast ductal adenocarcinomabreast ductal adenocarcinomabreast ductal adenocarcinoma: somatic 0.61brain gliomabrain gliomabrain glioma: somatic 0.61anaplastic astrocytomaanaplastic astrocytomaanaplastic astrocytoma: somatic 0.61breast lobular carcinomabreast lobular carcinomabreast lobular carcinoma: somatic 0.61skin basal cell carcinomaskin basal cell carcinomaskin basal cell carcinoma: somatic 0.61Brain Stem GlioblastomaBrain Stem GlioblastomaBrain Stem Glioblastoma: somatic 0.61squamous cell lung carcinomasquamous cell lung carcinomasquamous cell lung carcinoma: somatic 0.41lung carcinomalung carcinomalung carcinoma: somatic 0.46non-small cell lung carcinomanon-small cell lung carcinomanon-small cell lung carcinoma: somatic 0.46lung adenocarcinomalung adenocarcinomalung adenocarcinoma: somatic 0.46hepatocellular carcinomahepatocellular carcinomahepatocellular carcinoma: somatic 0.46

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

No positive tractability buckets.

gnomAD loss of function constraint: o/e 1.4902000427246094 (upper bound 2.3691999912261963). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of H3C2's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of H3C2's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.